Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease

Clinical Endocrinology

Volumn 60, Issue 6, 2004, Pages 694-698

  De Bellis, A ^a   Perrino, S ^a   Coronella, C ^a   Sansone, D ^a   Ruocco, G ^a   Tirelli, G ^a   Di Martino, S ^a   Conte, M ^a   Bellastella, G ^a   Wall, J R ^b   Bellastella, A ^a   Bizzarro, A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b GEELONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FLAVOPROTEIN ANTIBODY; G2S ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EVALUATION; EXTRAOCULAR MUSCLE; EYE DISEASE; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; IMMUNOFLUORESCENCE; LONGITUDINAL STUDY; MALE; PATIENT; PREDICTION; PRIORITY JOURNAL; SAMPLE; SCORING SYSTEM;

ACUTE DISEASE; ADULT; ANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EYE DISEASES; FEMALE; GRAVES DISEASE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OCULOMOTOR MUSCLES; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC;

EID: 2942703834     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02036.x     Document Type: Article

References (42)

1. Amato, G., Rotondi, M., Salzano, I., De Bellis, A., De Felice, G., Costagliola, C., Bellastella, A. & Carella, C. (2000) Extraocular muscle antibodies positivity as the only serum marker of euthyroid Graves' ophthalmopathy following subacute thyroiditis: case report. Journal of Clinical Endocrinology and Metabolism, 85, 950-952.
2. Bahn, R.S. (1996) A possible role for thyrotropin receptor in thyroid-associated ophthalmopathy. Orbit, 15, 119-128.
3. Bahn, R.S. (2003) Pathophysiology of Graves' ophthalmopathy: the cycle of disease. Journal of Clinical Endocrinology and Metabolism, 88, 1939-1946.
4. Bahn, R.S. & Heufelder, A.E. (1993) Pathogenesis of Graves' ophthalmopathy. New England Journal of Medicine, 329, 1468-1475.
5. Bartalena, L., Martino, E., Marcocci, C., Bogazzi, F., Panicucci, M., Velluzzi, F., Loviselli, A. & Pinchera, A. (1989) More on smoking habits and Graves' ophthalmopathy. Journal of Endocrinology Investigation, 12, 733-737.
6. Bartalena, L., Bogazzi, F., Tanda, M.L., Manetti, L., Dell'Unto, E. & Martino, E. (1995) Cigarette smoking and the thyroid. European Journal of Endocrinology, 133, 507-512.
7. Bartalena, L., Marcocci, C. & Pinchera, A. (1997) Treating severe Graves' ophthalmopathy. Bailliere's Clinical Endocrinology and Metabolism, 11, 521-536.
8. Bartalena, L., Marcocci, C., Tanda, M.L., Manetti, L., Dell'Unto, E., Bartolomei, M.P., Nardi, M., Martino, E. & Pinchera, A. (1998a) Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Annals of International Medicine, 129, 632-635.
9. Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M.L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M.P., Lepri, A., Rossi, G., Martino, E. & Pinchera, A. (1998b) Relation between therapy for hyperthyroidism and the corse of Graves' ophthalmopathy. New England Journal of Medicine, 338, 73-78.
10. Bartalena, L., Pinchera, A. & Marcocci, C. (2000) Management of Graves' ophthalmopathy: reality and perspectives. Endocrine Review of, 21, 168-199.
11. Bartalena, L., Marcocci, C. & Pinchera, A. (2002) Graves' ophthalmopathy: a preventable disease? European Journal of Endocrinology, 146, 457-461.
12. Burch, H.B. & Wartofsky, L. (1993) Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Review, 14, 747-793.
13. 111In-diethylenetriamine pentaacetic acid-D-Phe1]-octreotide predicts the clinical response to corticosteroid therapi in patients with Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 83, 3790-3894.
14. De Bellis, A., Bizzarro, A., Rossi, R., Amoresano Paglionico, V., Criscuolo, T., Lombardi, G. & Bellastella, A. (1993) Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. Journal of Clinical Endocrinology and Metabolism, 76, 1002-1007.
15. De Bellis, A., Bizzarro, A., Amoresano Paglionico, V., Di Martino, S., Criscuolo, T., Sinisi, A.A., Lombardi, G. & Bellastella, A. (1994) Detection of vasopressin cell antibodies in some patients with autoimmune endocrine disease without overt diabetes insipidus. Clinical Endocrinology, 40, 173-177.
16. De Bellis, A., Di Martino, S., Fiordelisi, F., Muccitelli, V.I., Sinisi, A.A., Abbate, G.F., Gargano, D., Bellastella, A. & Bizzarro, A. (1998) Soluble intercellular adhesion molecole-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 83, 1222-1225.
17. De Bellis, A., Colao, A., Bizzarro, A., Di Salle, F., Coronella, C., Solimeno, S., Vetrano, A., Pivonello, R., Pisano, G., Lombardi, G. & Bellastella, A. (2002) Longitudinal study of vasopressin cell antibodies and of hypothalamic-pituitary region on magnetic resonance imaging in patients with autoimmune and idiophatic complete central diabetes insipidus. Journal of Clinical Endocrinology and Metabolism, 87, 3825-3829.
18. De Bellis, A., Bizzarro, A., Conte, M., Coronella, C., Solimeno, S., Perrino, S., Sansone, D., Guaglione, M., Wall, J.R., Bellastella, A. (2003) Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. Clinical Endocrinology, 59, 388-395.
19. Feliciello, A., Porcellini, A., Ciullo, I., Bonavolontà, G., Avvedimento, E.V. & Fenzi, G. (1993) Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet, 342, 337-338.
20. Gorman, C.A. (1994) Pathogenesis of Graves' ophthalmopathy. Thyroid, 4, 379-383.
21. Gunji, K., De Bellis, A., Kubota, S., Swanson, J., Wengrowicz, S., Cochran, B., Ackrell, A.C., Salvi, M., Bellastella, A., Bizzarro, A., Sinisi, A. & Wall, J.R. (1999) Serum antibodies against the flavo-protein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 84, 1255-1262.
22. Gunji, K., De Bellis, A., Wu Li, A., Yamada, M., Kubota, S., Ackrell, B., Wengrowicz, S., Bellastella, A., Bizzarro, A., Sinisi, A. & Wall, J.R. (2000) Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 85, 1641-1647.
23. Heufelder, A.E. (1995) Pathogenesis of Graves' opthalmopathy: recent controversies and progress. European Journal of Endocrinology, 132, 532-541.
24. Kaspar, M., Archibald, C., De Bellis, A., Wu Li, A., Yamada, M., Chang, C., Kahaly, G. & Wall, J.R. (2002) Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy. Thyroid, 12, 187-191.
25. Kiljanski, J., Nebes, V. & Wall, J.R. (1995) The ocular muscle is the target of the immune system in endocrine ophthalmopathy. International Archive Allergy Immunology, 106, 204-212.
26. Kubota, S., Gunji, K., Ackrell, A.C., Cochran, B., Stolarski, C., Wengrowicz, S., Kennerdell, J.S., Hiromatsu, Y. & Wall, J.R. (1998) The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 83, 443-447.
27. Laureti, S., De Bellis, A., Muccitelli, V.I., Calcinaro, F., Bizzarro, A., Rossi, R., Bellastella, A., Santeusanio, F. & Falorni, A. (1998) Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. Journal of Clinical Endocrinology and Metabolism, 83, 3507-3511.
28. Ludgate, M., Crisp, M., Lane, C., Costagliola, S., Vassart, G., Weetman, A., Daunerie, C. & Many, M.C. (1998) The thyrotropin receptor in thyroid eye disease. Thyroid, 8, 411-413.
29. McGregor, A.M. (1998) Has the autoantigen for Graves' ophthalmopathy been found? Lancet, 352, 595-596.
30. Marcocci, C., Bartalena, L., Tanda, M.L., Manetti, L., Dell'Unto, E., Rocchi, R., Barbesino, G., Mazzi, B., Bartolomei, M.P., Lepri, P., Cartei, F., Nardi, M. & Pinchera, A. (2001) Comparison of effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopath: results of a prospective, single blind, randomized study. Journal of Clinical Endocrinology and Metabolism, 86, 3562-3567.
31. Mourits, M.P., Prummel, M.F., Wiersinga, W.M. & Koorneef, L. (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology, 47, 9-14.
32. Perros, P. & Kendall-Taylor, P. (1992) Antibodies to orbital tissue in thyroid-associated ophthalmopathy. Acta Endocrinologica, 126, 137-142.
33. Prummel, M.F., Wiersinga, W.M., Mouritz, M.P., Koorneef, L., Berghout, A. & van der Gaag, R. (1989) Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinologica, 121, 185-189.
34. Prummel, M.F., Wiersinga, W.M., Mouritz, M.P., Koorneef, L., Berghout, A. & van der Gaag, R. (1990) Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Archives of International Medicine, 150, 1098-1101.
35. Prummel, M.F., Suttorp-Schulten, M.S.A., Wiersinga, W.M., Verbeek, A.M., Mourits, M.P. & Koornneef, L. (1993) A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy. Ophthalmology, 100, 556-561.
36. Prummel, M.F., Bakker, A., Wiersinga, W.M., Baldeschi, L., Mourits, M.P., Kendall- Taylor, P., Perros, P., Neoh, C., Dickinson, A.J., Lazarus, J.H., Lane, C.M., Heufelder, A.E., Kahaly, G.J., Pitz, S., Orgiazzi, J., Hullo, A., Pinchera, A., Marcocci, C., Sartini, M.S., Rocchi, R., Nardi, M., Krassas, G.E. & Halkias, A. (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European group on Graves' orbitopathy experience. Europeaun Journal of Endocrinology, 148, 491-495.
37. Salvi, M., Miller, A. & Wall, J.R. (1988) Human orbital tissue and thyroid membranes express a 64-kDa protein which is recognized by auto-antibodies in the serum of patients with thyroid-associated ophthalmopathy. FEBS Letters, 232, 135-139.
38. Utech, C.J., Khatibnia, U., Winter, P.F. & Wulle, K.G. (1995) MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy. Thyroid, 5, 185-193.
39. Wakelkamp, I.M., Bakker, O., Baldeschi, L., Wiersinga, W.M. & Prummel, M.F. (2003) TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clinical Endocrinology, 58, 280-287.
40. Wall, J.R., Salvi, M., Bernard, N., Boucher, A. & Haegert, D. (1991) Thyroid-associated ophthalmopathy-A model for the association of organ-specific autoimmune disorder. Immunology Today, 12, 150-153.
41. Wiersinga, W.M. (1998) Preventing Graves' ophthalmopathy. New England Journal of Medicine, 338, 121-122.
42. Wiersinga, W.M. & Bartalena, L. (2002) Epidemiology and prevention of Graves' ophthalmopathy. Thyroid, 12, 855-860.